Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saunders, N. J.
Right arrow Articles by Lynn, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saunders, N. J.
Right arrow Articles by Lynn, W. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1995) 36, 729-736
© 1995 The British Society for Antimicrobial Chemotherapy

other

A prospective laboratory-based audit of gentamicin use and therapeutic monitoring

Nigel J. Saundersa, David J. Adamsb and William A. Lynnb

aDepartment of Infectious Diseases and Bacteriology Hammersmith Hospital, London W12 0NN bMolecular Infectious Diseases Group Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, 0X3 3DU, UK.

Received 15 November 1994; accepted 7 March 1995

We report a study investigating the proportion of patients in whom therapeutic serum concentrations of gentamicin are achieved in the early phase of treatment and to determine the underlying reasons for sub-optimal therapy. A laboratory based prospective study of 83 courses of gentamicin was performed (excluding patients receiving renal replacement therapy or with bacterial endocarditis) in a London teaching hospital. Of 83 monitored courses 74 had paired levels tested. Initial trough concentrations were >2 mg/L in nine (12%) and were <1 mg/L in 51 (69%) indicating levels were seldom in the toxic range. The first monitored peaks were sub-therapeutic in 58 (78%) courses using a cut-offof 5 mg/L and only seven (9%) were greater than 6 mg/L. Of these seven patients, six had troughs levels of greater than 2 mg/L. Of those with initial levels below 5 mg/L, 33 had further serum levels tested, of which 26 (79%) remained below 5 mg/L. Of those for whom dosing information was available 73% received 80 mg t.d.s. and the mean dose for those for which body weight was known was 3.3 mg/kg/day (s.d. = 0.7).

Most patients continued to receive 8-hourly dosing with 80 mg of gentamicin, leading to subtherapeutic peak levels in the majority of cases. In those patients with satisfactory peaks, such dosing frequently leads to elevated troughs. This suggests that such dosing practices should be abandoned and replaced with dosing based on body weight and divided into no more than two daily doses.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J.-R. Zahar, C. Rioux, E. Girou, A. Hulin, C. Sauve, A. Bernier-Combes, C. Brun-Buisson, and P. Lesprit
Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team
J. Antimicrob. Chemother., September 1, 2006; 58(3): 651 - 656.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.